ATE457351T1 - Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese - Google Patents

Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese

Info

Publication number
ATE457351T1
ATE457351T1 AT04812928T AT04812928T ATE457351T1 AT E457351 T1 ATE457351 T1 AT E457351T1 AT 04812928 T AT04812928 T AT 04812928T AT 04812928 T AT04812928 T AT 04812928T AT E457351 T1 ATE457351 T1 AT E457351T1
Authority
AT
Austria
Prior art keywords
ras
ksr
methods
expression
therapy
Prior art date
Application number
AT04812928T
Other languages
German (de)
English (en)
Inventor
Richard Kolesncik
Hongmei Xing
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE457351T1 publication Critical patent/ATE457351T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Animal Husbandry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04812928T 2003-12-03 2004-12-03 Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese ATE457351T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/727,358 US7301017B2 (en) 2002-05-30 2003-12-03 Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
PCT/US2004/040506 WO2005056756A2 (en) 2003-12-03 2004-12-03 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis

Publications (1)

Publication Number Publication Date
ATE457351T1 true ATE457351T1 (de) 2010-02-15

Family

ID=34677113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04812928T ATE457351T1 (de) 2003-12-03 2004-12-03 Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese

Country Status (8)

Country Link
US (3) US7301017B2 (https=)
EP (1) EP1697498B1 (https=)
JP (1) JP4855265B2 (https=)
AT (1) ATE457351T1 (https=)
AU (1) AU2004297594B2 (https=)
CA (1) CA2549384A1 (https=)
DE (1) DE602004025499D1 (https=)
WO (1) WO2005056756A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US8927598B2 (en) * 2008-01-30 2015-01-06 Duke University Treating oncogenic Ras driven cancers
WO2009137807A2 (en) * 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
CA2768042C (en) * 2009-07-24 2017-11-21 Universite De Montreal Bret-based biosensors and methods for monitoring raf dimerization
US8900845B2 (en) 2011-02-08 2014-12-02 Washington University Methods and uses of KSR kinase, and mutations thereof
US9526709B2 (en) * 2011-04-06 2016-12-27 Chemo-Enhanced Llc Compositions and methods for treating cancer
US9968570B2 (en) 2013-01-14 2018-05-15 Chemo-Enhanced Llc Compositions and methods for treating cancer
ES2879287T3 (es) * 2015-09-15 2021-11-22 Us Health Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8
KR101881874B1 (ko) * 2016-04-29 2018-07-26 한국수력원자력 주식회사 저선량 방사선 조사에 의한 암화 예방 방법
KR101875111B1 (ko) * 2016-04-29 2018-07-09 한국수력원자력 주식회사 저선량 방사선을 이용한 암화유전자 Ras-유도 악성 암화 억제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US591721A (en) 1897-10-12 Fan attachment
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6261834B1 (en) * 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
WO1994004672A1 (en) * 1992-08-26 1994-03-03 Dnx Corp. Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5792638A (en) * 1994-05-24 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Human ras-related oncogenes unmasked by expression cDNA cloning
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5700675A (en) * 1995-12-13 1997-12-23 Regents Of The University Of California Protein kinase required for Ras signal transduction
US5786213A (en) * 1996-04-18 1998-07-28 Board Of Regents, The University Of Texas System Inhibition of endogenous gastrin expression for treatment of colorectal cancer
GB9620749D0 (en) * 1996-10-04 1996-11-20 Brax Genomics Ltd Identifying antisense oligonucleotides
EP0943013A2 (en) * 1996-12-06 1999-09-22 Niels Pallisgaard Detection of chromosomal abnormalities
AU8280798A (en) * 1997-07-03 1999-01-25 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US6849334B2 (en) 2001-08-17 2005-02-01 Neophotonics Corporation Optical materials and optical devices
GB2335035B (en) * 1998-03-03 2003-05-28 Brax Genomics Ltd Screening for functional antisense agents
WO2001047944A2 (en) * 1999-12-28 2001-07-05 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
US6329203B1 (en) * 2000-09-08 2001-12-11 Isis Pharmaceuticals, Inc. Antisense modulation of glioma-associated oncogene-1 expression
US20030051267A1 (en) * 2001-05-10 2003-03-13 Pfizer Inc. Targeted disruption of kinase suppressor of RAS
US20030109466A1 (en) 2001-09-20 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of KSR expression
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US7528116B2 (en) * 2002-05-30 2009-05-05 Memorial Sloan Kettering Cancer Center Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20040265961A1 (en) * 2003-03-28 2004-12-30 Wei Liu Novel proteins homologous to kinase suppressor of Ras

Also Published As

Publication number Publication date
DE602004025499D1 (de) 2010-03-25
EP1697498A4 (en) 2007-10-31
EP1697498B1 (en) 2010-02-10
US20090143320A1 (en) 2009-06-04
US20080096840A1 (en) 2008-04-24
CA2549384A1 (en) 2005-06-23
US8283459B2 (en) 2012-10-09
EP1697498A2 (en) 2006-09-06
US20050037455A1 (en) 2005-02-17
JP2007512844A (ja) 2007-05-24
US7301017B2 (en) 2007-11-27
WO2005056756A3 (en) 2006-08-03
JP4855265B2 (ja) 2012-01-18
WO2005056756A2 (en) 2005-06-23
AU2004297594B2 (en) 2009-12-17
US8258108B2 (en) 2012-09-04
AU2004297594A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
ATE474045T1 (de) Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese
Pelechano et al. Gene regulation by antisense transcription
Thammaiah et al. Role of let-7 family microRNA in breast cancer
Babashah et al. Targeting of the signal transducer Smo links microRNA‐326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells
Song et al. The anti-miR21 antagomir, a therapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-associated miR30
Bernhardt et al. A viral microRNA cluster regulates the expression of PTEN, p27 and of a bcl-2 homolog
Okano et al. Small interfering RNA (siRNA) targeting of endogenous promoters induces DNA methylation, but not necessarily gene silencing, in rice
ATE457351T1 (de) Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese
Nosrati et al. DNA damage stress induces the expression of ribosomal protein S27a gene in a p53-dependent manner
TNSN08252A1 (en) Sirna anti myosine va et depigmentation de la peau
Li et al. The rheumatoid arthritis risk variant CCR6DNP regulates CCR6 via PARP-1
Detich et al. A conserved 3′-untranslated element mediates growth regulation of DNA methyltransferase 1 and inhibits its transforming activity
Katsushima et al. Long non-coding RNAs in brain tumors
Scheidegger et al. RNA polymerase II pausing as a context-dependent reader of the genome
Oganesian et al. 5′ C-rich telomeric overhangs are an outcome of rapid telomere truncation events
US20200102565A1 (en) Methods for overcoming glucocorticoid resistance and for determining glucocorticoid resistance potential in cancer
CN108285905A (zh) 一种基于CRISPR-Cas13a的抑制真核细胞中基因表达水平的方法及其应用
Park et al. Role of JAK2–STAT3 in TLR2‐mediated tissue factor expression
WO2004063331A3 (en) SiRNA MEDIATED POST-TRANSRIPTIONAL GENE SILENCING OF GENES INVOLVED IN ALOPECIA
MX2024000650A (es) Acido nucleico, composicion y conjugado que contiene el mismo, y metodo de preparacion y uso.
Carneiro et al. Evaluation of canonical siRNA and Dicer substrate RNA for inhibition of hepatitis C virus genome replication–a comparative study
Master et al. A novel method for gene-specific enhancement of protein translation by targeting 5’UTRs of selected tumor suppressors
Rezzoug et al. Discovery of a family of genomic sequences which interact specifically with the c-MYC promoter to regulate c-MYC expression
Audic et al. Zygotic control of maternal cyclin A1 translation and mRNA stability
DE602007008918D1 (de) Sensibilisierung von krebszellen für eine therapie unter verwendung von sina-zielgenen aus den chromosomenregionen 1p und 19q

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties